Lumakras
sotorasib · KRAS G12CDerivation not stated; clinical exposures at 180-960 mg were below those at the rat STD10 but above those at the dog HNSTD
The public FDA and EMA reviews of Fruzaqla don't say how the first human dose was chosen. That rationale is in the IND, which is confidential, so it is missing for most approved products.
In cancer patients the start dose should be pharmacologically active yet reasonably safe. A common small-molecule approach is one-tenth of the dose severely toxic to 10% of rodents, or one-sixth of the highest non-severely toxic dose in non-rodents.
NOAEL / key findings: Target organs: liver, kidney, adrenal gland, thymus, spleen, bone marrow and femur (EMA assessment report, p. 40)